Novel Antibody and Assay for Early-stage Detection and Treatment Optimization of ALS, FTD, LATE and AD

Peak revenue. The asset is not modeled as a mass-market Alzheimer mAb because TDP-43-positive ALS/FTD/LATE subsets are narrower and clinically harder. The $800M peak sits between tofersen-scale ALS precision medicine and lecanemab-scale CNS mAb upside.

WACC. CNS biologic development has high translational and endpoint risk despite meaningful strategic interest.

The TDP-43 antibody asset targets a real neurodegeneration biology node: TDP-43 dysfunction links ALS, FTD, LATE, and subsets of Alzheimer's disease through cryptic-exon mis-splicing and proteinopathy. Its top-10 position is strongest on clinical relevance and biomarker definition, not on near-term development simplicity.

**Mechanism class — the load-bearing diligence question.** Native TDP-43 is a nuclear/cytoplasmic protein and conventional IgG cannot reach intracellular targets, so any thesis that paraphrases the asset as a 'TDP-43 antibody' without specifying the tractable form is a CMO-grade red flag. The JHU listing is explicit on this point: the antibody binds a **TDP-43-dependent cryptic-exon-encoded neoantigen** — a de novo peptide produced when loss of TDP-43 splicing repression admits cryptic exons into transcripts like HDGFL2, STMN2, and UNC13A. This places the asset in the cryptic-peptide neoantigen mechanism class, and the closest published precedent is the Hopkins TC1HDG sandwich-ELISA work (Irwin et al., Nature Medicine 2024) showing the HDGFL2 cryptic peptide is detectable in CSF of pre-symptomatic C9orf72 carriers, with a 2026 medRxiv preprint extending the same biology to a NfL-to-HDGFL2 ratio biomarker. The patent itself describes a monoclonal antibody plus ELISA detection assay — i.e., the disclosed use is diagnostic, and the therapeutic interpretation rests on the inference that cryptic-peptide neoepitopes detectable extracellularly (CSF and serum extracellular vesicles, per Tachi et al. 2026) can in principle be engaged by an extracellular mAb. That inference is the first thing a CMO advisor will probe; treat it as the diligence anchor, not as settled biology. Adjacent mechanism classes that solve the same intracellular-target problem differently — misfolded-extracellular TDP-43 selectivity (ProMIS PMN267 archetype, currently in development as both an extracellular antibody and an intrabody) and AAV-delivered intrabody (Mabylon/AC Immune ACI-5891 archetype, 58–68% phospho-TDP-43 reduction in mouse via intracisternal AAV9 vmAb) — exist as alternative interpretations of a 'TDP-43 antibody' label, but the JHU listing language does not support them and reframing the asset as either would misrepresent the disclosed invention.

QALSODY provides the most useful ALS regulatory analogy because it shows that a genetically or biomarker-defined ALS subgroup can reach approval on a serious-disease pathway. LEQEMBI and Aduhelm add the CNS-antibody lesson: approved mAbs can unlock large markets, but endpoint scrutiny, safety monitoring, and uptake friction are real. The engine result is -$54.3M to $34.1M, with a base rNPV of -$10.1M and cumulative PoS of 8.0%; that supports the VC-fundable label only if the first indication is a tightly defined ALS/FTD subgroup rather than a broad Alzheimer's launch.

The verdict is a high-upside, high-scrutiny CNS biologic. The asset earns its top-10 ranking because it combines major unmet need with a plausible biomarker story, but the funding case depends on proving (a) that the cryptic-peptide neoepitope is genuinely druggable as a therapeutic target and not only as a diagnostic biomarker, and (b) that target engagement can be measured in the absence of a regulatory-validated assay.